NASDAQ:IONSIonis Pharmaceuticals Stock Price, Forecast & News

Ionis Pharmaceuticals' stock was trading at $49.14 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IONS shares have increased by 10.8% and is now trading at $54.47. View which stocks have been most impacted by Coronavirus.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 1 sell rating, 7 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Ionis Pharmaceuticals.

Ionis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Ionis Pharmaceuticals.

Ionis Pharmaceuticals Inc (NASDAQ:IONS) posted its earnings results on Wednesday, May, 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.23. The business had revenue of $133 million for the quarter, compared to analyst estimates of $161.59 million. Ionis Pharmaceuticals had a net margin of 16.79% and a return on equity of 12.50%. The firm's quarterly revenue was down 55.2% on a year-over-year basis. During the same quarter last year, the company posted $0.62 earnings per share. View Ionis Pharmaceuticals' earnings history.

Ionis Pharmaceuticals issued an update on its FY 2020 Pre-Market earnings guidance on Wednesday, February, 26th. The company provided EPS guidance of for the period. The company issued revenue guidance of $700 million, compared to the consensus revenue estimate of $814.68 million.

16 equities research analysts have issued 12 month target prices for Ionis Pharmaceuticals' stock. Their forecasts range from $51.00 to $120.00. On average, they anticipate Ionis Pharmaceuticals' stock price to reach $74.21 in the next twelve months. This suggests a possible upside of 36.2% from the stock's current price. View analysts' price targets for Ionis Pharmaceuticals.

News articles about IONS stock have trended negative recently, according to InfoTrie Sentiment. The research firm rates the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Ionis Pharmaceuticals earned a coverage optimism score of -2.1 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutIonis Pharmaceuticals.

Some companies that are related to Ionis Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Exelixis (EXEL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), Alibaba Group (BABA), BlackRock (BLK), Gilead Sciences (GILD), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), NVIDIA (NVDA), Intercept Pharmaceuticals (ICPT) and Skyworks Solutions (SWKS).

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Ionis Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (6.28%), BlackRock Inc. (5.86%), Clearbridge Investments LLC (5.77%), Wellington Management Group LLP (2.86%), Invesco Ltd. (1.68%) and Waddell & Reed Financial Inc. (1.55%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke. View institutional ownership trends for Ionis Pharmaceuticals.

IONS stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Bank of New York Mellon Corp, Raymond James & Associates, JPMorgan Chase & Co., BlackRock Inc., Deutsche Bank AG, Two Sigma Advisers LP, and Russell Investments Group Ltd.. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include Brett P Monia, Elizabeth L Hougen, Frederick T Muto, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen, and Stanley T Crooke. View insider buying and selling activity for Ionis Pharmaceuticals.

IONS stock was bought by a variety of institutional investors in the last quarter, including Rockefeller Capital Management L.P., Swiss National Bank, Clearbridge Investments LLC, Aviva PLC, Sector Gamma AS, Federated Hermes Inc., Trexquant Investment LP, and Geode Capital Management LLC. View insider buying and selling activity for Ionis Pharmaceuticals.

Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of IONS stock can currently be purchased for approximately $54.47.

Ionis Pharmaceuticals has a market capitalization of $7.59 billion and generates $1.12 billion in revenue each year. The company earns $303.26 million in net income (profit) each year or $2.08 on an earnings per share basis. Ionis Pharmaceuticals employs 737 workers across the globe.

The official website for Ionis Pharmaceuticals is www.ionispharma.com.

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200.